title: Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.
abstract: The Wnt signaling pathways are a group of signal transduction pathways that play an important role in cell fate specification, cell proliferation and cell migration. Aberrant signaling in these pathways has been implicated in the development and progression of multiple cancers by allowing increased proliferation, angiogenesis, survival and metastasis. Activation of the Wnt pathway also contributes to the tumorigenicity of cancer stem cells (CSCs). Therefore, inhibiting this pathway has been a recent focus of cancer research with multiple targetable candidates in development. OMP-54F28 is a fusion protein that combines the cysteine-rich domain of frizzled family receptor 8 (Fzd8) with the immunoglobulin Fc domain that competes with the native Fzd8 receptor for its ligands and antagonizes Wnt signaling. Preclinical models with OMP-54F28 have shown reduced tumor growth and decreased CSC frequency as a single agent and in combination with other chemotherapeutic agents. Due to these findings, a phase 1a study is nearing completion with OMP-54F28 in advanced solid tumors and 3 phase 1b studies have been opened with OMP-54F28 in combination with standard-of-care chemotherapy backbones in ovarian, pancreatic and hepatocellular cancers. This article will review the Wnt signaling pathway, preclinical data on OMP-54F28 and other Wnt pathway inhibitors and ongoing clinical trials.
authors.affiliation: University of Colorado School of Medicine, Division of Medical Oncology, United States.
authors.forename: Phuong N
authors.initials: PN
authors.lastname: Le
authors.affiliation: University of Colorado School of Medicine, Division of Medical Oncology, United States.
authors.forename: Jessica D
authors.initials: JD
authors.lastname: McDermott
authors.affiliation: University of Colorado School of Medicine, Division of Medical Oncology, United States. Electronic address: Antonio.jimeno@ucdenver.edu.
authors.forename: Antonio
authors.initials: A
authors.lastname: Jimeno
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D060449:Wnt Signaling Pathway / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D007141:Immunoglobulin Fc Fragments; D043562:Receptors, G-Protein-Coupled; D011993:Recombinant Fusion Proteins; C000601924:OMP-54F28
keywords: Frizzled family receptor 8; OMP-54F28; Wnt inhibitor